Figure 5

Neutralization of pseudovirus infection by tetramerized clinical stage SARS-CoV-2 antibodies. The potency of clinical stage mAbs that were engineered as tetramer formats was measured in SARS-CoV-2 pseudovirus infection assays. Increasing concentrations of antibodies were incubated with Wuhan pseudovirus for 1 h before addition to HEK 293 T/1A2-T2 cells. The cells were incubated for 60 h before luciferase activity was determined to show viral entry. The data are split to different panels for clarity. (A) The neutralization potency of H4-scFv-TD Quad was compared to clinical stage REGN10987, REGN10933 and CB6/Junshi IgG1. (B) The neutralization potency of REGN10987, REGN10933 and CB6/Junshi IgG1 was compared to REGN10987 Fab-TD, CB6/Junshi Fab-TD and REGN10933 Fab-TD. (C) The neutralization potency of the REGN10987, REGN10933 and CB6/Junshi IgG1 was compared to REGN10987 mIg-TD, REGN10987 mIg-TD and CB6/Junshi mIg-TD. (D) The neutralization potency of the REGN10987, REGN10933 and CB6/Junshi IgG1 was compared to REGN10987 Ig-TD, CB6/Junshi Ig-TD and REGN10933 Ig-TD. The assays were performed twice and each point in duplicate. The error bars indicate the standard errors. Computed IC₅₀ data (nM and µg/ml) and fold change based on nM are shown in Supplementary Fig. 4. Tetramerised clinical stage mAbs potency neutralisation potency was measured against SARS-CoV-2 pseudovirus variants by increasing concentrations of antibodies incubated with Wuhan, B.1.1.7 or B.1.351 pseudoviruses. (E) Neutralization potency of REGN10933 IgG1, Fab-TD, mIg-TD and Ig-TD against Wuhan, B.1.1.7 and B.1.351 pseudoviruses (F) Neutralization potency of REGN10987 IgG1, Fab-TD, mIg-TD and Ig-TD against Wuhan, B.1.1.7 and B.1.351 pseudoviruses (G) The neutralization potency of CB6/Junshi IgG1, Fab-TD, mIg-TD and Ig-TD against Wuhan, B.1.1.7 and B.1.351 pseudoviruses. The assays were performed twice and each point in duplicate. The error bars indicate standard deviations.